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ibrosing mediastinitis is a rare benign disorder with an eti-
ology that commonly remains unknown, although tuber-
culosis, syphilis, histoplasmosis, and blastomycosis have
been all considered potential etiologic factors. It is charac-
terized by focal or diffuse proliferation of acellular collagen and
fibrous tissue within the mediastinum, which mimic malignancy.
About 40% of patients have the disease discovered incidentally dur-
ing their young-middle age, but the rest have symptoms of compres-
sion of mediastinal structures, the superior vena cava being the most
common clinically.1
Until a few years ago, superior vena cava replacement was the
only effective treatment for superior vena cava syndrome resulting
from fibrosing mediastinitis.
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fered a new, attractive, and patient-friendly therapeutic option, al-
though questions remain regarding long-term outcome and the
optimal treatment strategy for stenting failures.2,3 In fact, removal
of the stent is often impossible in these instances and superior
vena cava resection and reconstruction can result in a technically de-
manding surgical procedure, particularly when the fibrotic mass in-
volves other vital mediastinal structures such as pulmonary artery
and main stem bronchi.
Herein we report the case histories of 2 patients with idiopathic
fibrosing mediastinitis who underwent initial successful superior
vena cava stenting but had subsequent occlusion of the stent, which
was treated by a nonresectional extra-anatomic bypass of the supe-
rior vena cava.
Clinical Summaries
PATIENT 1. A 45-year-old woman was admitted with dyspnea
and dilated veins over the chest.
The patient history began 6 years earlier when she had superior
vena cava syndrome. A computed tomographic (CT) scan of the
chest showed a mediastinal mass involving the middle and anterosu-
perior mediastinum encasing and compressing the superior vena
cava and the left innominate vein. Surgical biopsy through anterior
mediastinotomy led to diagnosis of fibrosing mediastinitis. At that
time, the patient was treated by endovascular placement of a metal
stent in the superior vena cava, which resulted in disappearance of
symptoms. The patient remained free of symptoms for 3 years,
but afterward neck swelling, dyspnea, and chest vein dilatation
recurred. A chest CT scan demonstrated a slight enlargement of
the mediastinal mass with occlusion of the stent and development
of superior–inferior vena cava collateral circulation (Figure 1).
After admission to our department, it was decided to perform an
extra-anatomic bypass of the superior vena cava, which was easily
carried out without resection of the mediastinal mass (Figure 2,
A). Total operative time was 90 minutes and the patient wasFigure 1. Preoperative computed tomographic
scan: A, An angiogram shows absence of flow
in the stented superior vena cava with develop-
ment of superior–inferior vena cava collateral
circulation via right lateral thoracic and hemiazy-
gous veins. B, Axial view illustrates the mediasti-
nal fibrotic mass encasing the occluded metal
stent.uary 2008
Brief CommunicationsFigure 2. A, Intraoperative view of the extra-ana-
tomic polytetrafluoroethylene graft bypass (G),
right atrium (RA), and fibrotic mass encasing the
stented superior vena cava (M). B, Coronal 3-di-
mensional reconstruction of the mediastinum
depicts both the occluded metal stent and patent
polytetrafluoroethylene graft.discharged 4 days after the operation on a regimen of anticoagulant
therapy.
A radiogram obtained 36 months after the operation showed
a fully patent graft (Figure 2, B) and a relatively stable mediastinal
mass (Figure E1).
PATIENT 2. A 48-year-old woman had a cough and swollen, di-
lated veins of the face and upper extremities. She had normal lung
function and blood tests. A CT scan confirmed a mass in the medi-
astinum and videomediastinoscopy permitted diagnosis of fibrosing
mediastinitis. Endovascular stenting of the superior vena cava re-
sulted in resolution of symptoms. Eighteen months later symptoms
recurred owing to obstruction of the stent, and extra-anatomic supe-
rior vena cava bypass was successfully carried out as previously de-
scribed. So far, the patient remains free of symptoms with a patent
graft 14 months after the operation.
Discussion
In patients with superior vena cava obstruction owing to fibrosing
mediastinitis, either vena cava replacement or endovascular stenting
has been used with satisfactory results and primary patency rates of
63%2 and 21%,3 respectively.
We have hypothesized that a step-by-step strategy including ini-
tial stenting followed by subsequent vena cava replacement at the
reappearance of disabling symptoms could assure more prolonged
benefits than each single modality per se. It is also conceivable
that a multistep approach including initial stenting, subsequent
bypass, and additional secondary endovascular treatment might be
considered as well.
We also believed that whenever radiologic imaging shows a focal
disease, an extra-anatomic bypass performed with no resection ofThe Journal of Thorthe vena cava, and possibly distant from the mediastinal lesion,
could shorten the operative time and minimize the risk of an early
involvement of the graft because of disease progression.
Efficacy of polytetrafluoroethylene for superior vena cava
replacement in benign disorders has been questioned, assuming
better results with venous autografts.4 However, within our surgical
experience with superior vena cava replacement,5 we have used
polytetrafluoroethylene since 1987 with satisfactory results. In these
instances, to minimize the risk of graft occlusion, we tailor anticoag-
ulants to keep the international normalized ratio between 2.8 and
3.0.
In conclusion, an integrated treatment strategy entailing initial
stenting followed by nonresectional extra-anatomic bypass of the
superior vena cava allowed prolonged benefit in 2 patients with
severely symptomatic fibrosing mediastinitis.
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Brief CommunicationsFigure E1. Postoperative computed tomographic
scan at 36 months: A, An angiogram shows the
patent graft with normalization of the collateral
circulation depicted preoperatively. B, Axial
view illustrates the relatively stable mediastinal
mass and the graft, which lies in the anterior me-
diastinum but distant from the disease process.221.e1 The Journal of Thoracic and Cardiovascular Surgery c January 2008
